Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMENOS: Trastuzumab Emtansine for HER2-positive Extramammary Paget's Disease
jRCTs031200064Phase 2Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in extramammary Paget disease (EMPD), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Objective response rate after 3 cycles. Started Mar 2021; status: active, not recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on jRCTs031200064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200064.